See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Motorsports
Pope Francis
Baseball
South America
NFL
Social Media
US Politics
Natural Disasters
Wrestling
Donald Trump
Soccer
Tariffs
Published • loading... • Updated

JP Morgan 2025: AbbVie counts on Skyrizi and Rinvoq to fill Humira-sized hole

Summary
AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira sales drop.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Clinical Trials ArenaClinical Trials Arena

JP Morgan 2025: Jazz Pharmaceuticals focusing on oncology pipeline

JP Morgan attendees were told of Jazz Pharmaceuticals' plans to expand indications for two oncology drugs: zanidatamab and Zepzelca.The post JP Morgan 2025: Jazz Pharmaceuticals focusing on oncology pipeline appeared first on Clinical Trials Arena.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Clinical Trials Arena broke the news in on Wednesday, January 15, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

JP Morgan

JP Morgan

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal